Baerwald C, Goebel K M, Krause A, Heymanns J
Zentrum Innere Medizin der Universität Marburg/Lahn.
Schweiz Med Wochenschr. 1989 Dec 9;119(49):1769-71.
Ciamexone, a 2-cyanoaziridine derivative, had been shown previously in animal studies to inhibit the proliferation of autoreactive lymphocytes dose dependently, without affecting the reaction against foreign antigens. To extend the experimental models of ciamexone's in vitro effects to the clinical level, we performed a pilot study to evaluate the clinical efficacy of ciamexone therapy. We further studied its influence on the systemic inflammatory activity and T-lymphocyte subsets in the peripheral blood of 10 patients with active rheumatoid arthritis (RA). Following 6 months' treatment with ciamexone all patients showed a significant decrease of both the clinical and biochemical scores. Concerning the T-lymphocyte subsets analysis, a relatively decreased rate of the activated T-lymphocytes was observed concurrently. Minor side effects included rash (n = 1), hepatotoxicity (n = 1) and diarrhea (n = 1). The study thus documents the clinical efficacy of ciamexone in patients with RA, but also indicates the agent's potential toxicity.
齐美利定，一种2-氰基氮杂环丙烷衍生物，此前在动物研究中已表明其可剂量依赖性地抑制自身反应性淋巴细胞的增殖，而不影响对外源抗原的反应。为了将齐美利定体外作用的实验模型扩展到临床层面，我们进行了一项试点研究以评估齐美利定治疗的临床疗效。我们进一步研究了其对10例活动期类风湿关节炎（RA）患者外周血中全身炎症活性和T淋巴细胞亚群的影响。在用齐美利定治疗6个月后，所有患者的临床和生化评分均显著降低。关于T淋巴细胞亚群分析，同时观察到活化T淋巴细胞的相对降低率。轻微的副作用包括皮疹（n = 1）、肝毒性（n = 1）和腹泻（n = 1）。该研究因此证明了齐美利定对RA患者的临床疗效，但也表明了该药物的潜在毒性。
